GlobeStar Therapeutics Corp: 10-Q filed 2016-06-16

Name: GlobeStar Therapeutics Corp: 10-Q filed 2016-06-16
Creator: GlobeStar Therapeutics Corp

What GlobeStar Therapeutics Corp reported in its quarterly report filed 2016-06-16 (fiscal Q2 2016): 19 published measures, 51 facts as tagged in accession 0001161697-16-000897.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-06-16
Fiscal period: fiscal Q2 2016
Accession: 0001161697-16-000897 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2016-03-31	311,540	USD
At 2015-09-30	322,313	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2016-03-31	539,460	USD
At 2015-09-30	309,672	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2016-03-31	-227,920	USD
At 2015-09-30	12,641	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2016-03-31	38,799	USD
At 2015-09-30	5,687	USD
At 2015-03-31	3,131	USD
At 2014-09-30	1,211	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-209,677	USD	91
2015-10-01 to 2016-03-31	-417,204	USD	183
2015-01-01 to 2015-03-31	-304,278	USD	90
2014-10-01 to 2015-03-31	-529,920	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2015-10-01 to 2016-03-31	-128,751	USD	183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-03-31	-4,859,641	USD
At 2015-09-30	-4,442,437	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-96,396	USD	91
2015-10-01 to 2016-03-31	-227,937	USD	183
2015-01-01 to 2015-03-31	-149,867	USD	90
2014-10-01 to 2015-03-31	-248,076	USD	182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2016-03-31	46,364	USD
At 2015-09-30	11,180	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	113,281	USD	91
2015-10-01 to 2016-03-31	189,267	USD	183
2015-01-01 to 2015-03-31	154,411	USD	90
2014-10-01 to 2015-03-31	281,844	USD	182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-03-31	494,242	USD
At 2015-09-30	246,830	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2016-03-31	6,065	USD
At 2015-09-30	4,794	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	102,297	USD	91
2015-10-01 to 2016-03-31	242,292	USD	183
2015-01-01 to 2015-03-31	153,103	USD	90
2014-10-01 to 2015-03-31	270,473	USD	182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2016-03-31	10,022,543	shares
At 2015-09-30	8,793,418	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2016-03-31	4,626,588	USD
At 2015-09-30	4,424,006	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2016-03-31	-5,890	USD
At 2015-09-30	21,279	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-234,906	USD	91
2015-10-01 to 2016-03-31	-444,373	USD	183
2015-01-01 to 2015-03-31	-301,367	USD	90
2014-10-01 to 2015-03-31	-526,990	USD	182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	97,037	USD	91
2015-10-01 to 2016-03-31	215,628	USD	183
2015-01-01 to 2015-03-31	142,396	USD	90
2014-10-01 to 2015-03-31	246,822	USD	182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2015-10-01 to 2016-03-31	1,271	USD	183
2014-10-01 to 2015-03-31	-9,825	USD	182

Inspect the source

Entity: GlobeStar Therapeutics Corp / CIK 0001502152
Captured: 2026-09-21T17:19:31.788Z
SEC response SHA-256: 6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))